Source comparison
PT-141 Differs from Viagra: Medication Comparison
Primary Mechanism Melanocortin receptor (MC3R/MC4R) agonist in the hypothalamus. Modulates dopamine and oxytocin pathways to increase sexual desire centrally PDE5 inhibitor in vascular smooth muscle. Increases cGMP to enhance blood flow to erectile tissue peri
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Melanocortin receptor (MC3R/MC4R) agonist in the hypothalamus. Modulates dopamine and oxytocin pathways to increase sexual desire centrally
- PDE5 inhibitor in vascular smooth muscle. Increases cGMP to enhance blood flow to erectile tissue peripherally
- PT-141 addresses desire; Viagra addresses mechanics
- Target Patient Profile
- Hypoactive sexual desire disorder (HSDD), SSRI-induced libido loss, neurological conditions affecting arousal motivation
- Erectile dysfunction with intact libido. Vascular insufficiency, diabetic neuropathy, age-related endothelial impairment
- Match mechanism to symptom. Low desire vs impaired erection
- Administration Route
- Subcutaneous injection (1.75 mg) in abdomen or thigh 45–60 min before activity
- Oral tablet (25–100 mg) 30–60 min before activity on empty stomach
- Injection allows CNS access; oral route requires hepatic metabolism
- Onset & Duration
- 30–45 min onset, 6–12 hr sustained effect, peak at 1 hr
- 30–60 min onset (longer with food), 4–5 hr effect, peak at 60–120 min
- PT-141 less affected by meals; Viagra timing food-dependent
- Most Common Side Effect
- Nausea (40% at 1.75 mg dose), transient BP elevation (+5–10 mmHg)
- Headache (16–28%), facial flushing (10–15%), nasal congestion (4–9%)
- Nausea manageable with ondansetron; headache with NSAIDs
- Key Contraindication
- Uncontrolled hypertension (systolic >160 mmHg)
- Concurrent nitrate therapy (nitroglycerin, isosorbide)
- Check BP for PT-141; check cardiac meds for Viagra